PDCD1 and non-small cell lung carcinoma: The POPLAR trial(Fehrenbacher et al. 2016) and OAK trial (Rittmeyer et al. 2017) have indicated promising anticancer activity in pretreated metastatic nonsquamous PD-1-positive NSCLC, with median OS times of 12.6 months (95% confidence interval [CI] 9.7–16.4) and 13.8 months (11.8–15.7), respectively.